Dr Fran Priddy: New Zealand’s unique study on the Pfizer vaccine

New Zealand’s ‘COVID-naive’ population will offer unique data to global research as part of a new clinical study looking at how our bodies respond to the Pfizer-BioNTech vaccine.

The study ‘Ka Matau, Ka Ora’ is being led by Vaccine Alliance Aotearoa New Zealand (VAANZ) and is currently underway in Rotorua and Christchurch.

VAANZ clinical director Fran Priddy says while the vaccine has demonstrated efficacy and safety in pivotal clinical trials and real-world studies, it has not yet been studied in New Zealand. With vaccine safety being closely monitored around the globe,

‘Ka Matau, Ka Ora’ will focus on characterising immune responses, particularly in populations at higher risk from Covid-19 such as Maori, Pasifika and the elderly.

Dr Fran Priddy: New Zealand’s unique study on the Pfizer vaccine
0:00 / 21:41